A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study.
dizziness
galcanezumab
vestibular migraine
Journal
Headache
ISSN: 1526-4610
Titre abrégé: Headache
Pays: United States
ID NLM: 2985091R
Informations de publication
Date de publication:
30 Sep 2024
30 Sep 2024
Historique:
revised:
02
08
2024
received:
13
04
2024
accepted:
03
08
2024
medline:
30
9
2024
pubmed:
30
9
2024
entrez:
30
9
2024
Statut:
aheadofprint
Résumé
To study if galcanezumab is effective for vestibular migraine (VM). There are currently no placebo-controlled trials showing that treatment is effective for VM. Therefore, we performed the first placebo controlled, randomized clinical trial of a calcitonin gene-related peptide-targeted monoclonal antibody for VM. This was a single site, prospective, double-blind placebo controlled randomized clinical trial. Key inclusion criteria were as follows: participants aged 18-75 years with a diagnosis of VM or probable VM per Barany Society criteria. The primary outcome was change in VM-PATHI (Vestibular Migraine Patient Assessment Tool and Handicap Inventory) score, and secondary outcomes included change in DHI (Dizziness Handicap Inventory) score, and count of definite dizzy days (DDDs). Participants were randomized 1:1 to 3 months of treatment with galcanezumab or placebo via subcutaneous injection with a pre-filled syringe, 240 mg the first month, and 120 mg for the second and third months. Forty participants were randomized, and 38 participants were in the modified intent to treat analysis. VM-PATHI score was reduced 5.1 points (95% confidence interval [CI] -13.0 to 2.7) for placebo (N = 21), and 14.8 points (95% CI -23.0 to -6.5) for galcanezumab (N = 17), a difference of -9.6 (95% CI -20.7 to 1.5, p = 0.044). DHI dropped 8.3 points in the placebo arm (95% CI -15.0 to 1.6), and 22.0 points in the galcanezumab arm (95% CI -31.9 to -12.1), a difference of -13.7 (95% CI -20.4 to -8.5, p = 0.018). The count of DDDs per month dropped from 18 days (standard deviation [SD] 7.6) in the baseline month to 12.5 days (SD 11.2) in month 4 for those in the placebo arm, and from 17.9 days (SD 7.9) in the baseline month to 6.6 days (SD 7.3) in month 4 for those in the galcanezumab arm, a difference of -5.7 days (95% CI -10.7 to -0.7, p = 0.026). No serious adverse events were observed. In this pilot study, galcanezumab was effective in treating VM.
Sections du résumé
OBJECTIVE
OBJECTIVE
To study if galcanezumab is effective for vestibular migraine (VM).
BACKGROUND
BACKGROUND
There are currently no placebo-controlled trials showing that treatment is effective for VM. Therefore, we performed the first placebo controlled, randomized clinical trial of a calcitonin gene-related peptide-targeted monoclonal antibody for VM.
METHODS
METHODS
This was a single site, prospective, double-blind placebo controlled randomized clinical trial. Key inclusion criteria were as follows: participants aged 18-75 years with a diagnosis of VM or probable VM per Barany Society criteria. The primary outcome was change in VM-PATHI (Vestibular Migraine Patient Assessment Tool and Handicap Inventory) score, and secondary outcomes included change in DHI (Dizziness Handicap Inventory) score, and count of definite dizzy days (DDDs). Participants were randomized 1:1 to 3 months of treatment with galcanezumab or placebo via subcutaneous injection with a pre-filled syringe, 240 mg the first month, and 120 mg for the second and third months.
RESULTS
RESULTS
Forty participants were randomized, and 38 participants were in the modified intent to treat analysis. VM-PATHI score was reduced 5.1 points (95% confidence interval [CI] -13.0 to 2.7) for placebo (N = 21), and 14.8 points (95% CI -23.0 to -6.5) for galcanezumab (N = 17), a difference of -9.6 (95% CI -20.7 to 1.5, p = 0.044). DHI dropped 8.3 points in the placebo arm (95% CI -15.0 to 1.6), and 22.0 points in the galcanezumab arm (95% CI -31.9 to -12.1), a difference of -13.7 (95% CI -20.4 to -8.5, p = 0.018). The count of DDDs per month dropped from 18 days (standard deviation [SD] 7.6) in the baseline month to 12.5 days (SD 11.2) in month 4 for those in the placebo arm, and from 17.9 days (SD 7.9) in the baseline month to 6.6 days (SD 7.3) in month 4 for those in the galcanezumab arm, a difference of -5.7 days (95% CI -10.7 to -0.7, p = 0.026). No serious adverse events were observed.
CONCLUSIONS
CONCLUSIONS
In this pilot study, galcanezumab was effective in treating VM.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Eli Lilly and Company
Informations de copyright
© 2024 American Headache Society.
Références
Formeister EJ, Rizk HG, Kohn MA, Sharon JD. The epidemiology of vestibular migraine: a population‐based survey study. Otol Neurotol. 2018;39(8):1037‐1044.
Lempert T, Olesen J, Furman J, et al. Vestibular migraine: diagnostic criteria. J Vestib Res. 2012;22(4):167‐172.
Benjamin T, Gillard D, Abouzari M, Djalilian HR, Sharon JD. Vestibular and auditory manifestations of migraine. Curr Opin Neurol. 2022;35(1):84‐89.
Preysner TA, Gardi AZ, Ahmad S, Sharon JD. Vestibular migraine: cognitive dysfunction, mobility, falls. Otol Neurotol. 2022;43(10):1216‐1221.
Chae R, Krauter R, Pasquesi LL, Sharon JD. Broadening vestibular migraine diagnostic criteria: a prospective cohort study on vestibular migraine subtypes. J Vestib Res. 2022;32(5):453‐463.
Benjamin T, Gardi A, Sharon JD. Recent developments in vestibular migraine: a narrative review. Am J Audiol. 2023;32:739‐745.
Zhu RT, Van Rompaey V, Ward BK, Van de Berg R, Van de Heyning P, Sharon JD. The interrelations between different causes of dizziness: a conceptual framework for understanding vestibular disorders. Ann Otol Rhinol Laryngol. 2019;128(9):869‐878.
Mallampalli MP, Rizk HG, Kheradmand A, et al. Care gaps and recommendations in vestibular migraine: an expert panel summit. Front Neurol. 2021;12:812678.
Webster K, Dor A, Galbraith K, et al. Pharmacological interventions for prophylaxis of vestibular migraine. Cochrane Database Syst Rev. 2023;2023(4):CD015187.
Webster KE, Dor A, Galbraith K, et al. Pharmacological interventions for acute attacks of vestibular migraine. Cochrane Database Syst Rev. 2023;4(4):CD015322.
Bayer O, Adrion C, Al Tawil A, Mansmann U, Strupp M, PROVEMIG Investigators. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG). Trials. 2019;20(1):813.
Ferrari MD, Goadsby PJ, Burstein R, et al. Migraine. Nat Rev Dis Primers. 2022;8(1):2.
Russo CV, Saccà F, Braca S, et al. Anti‐calcitonin gene‐related peptide monoclonal antibodies for the treatment of vestibular migraine: a prospective observational cohort study. Cephalalgia. 2023;43(4):3331024231161809.
Rahman SM, Hauser C, Faucher S, Fine E, Luebke AE. Both systemic calcitonin gene related peptide (CGRP) and a vestibular challenge promote anxiety‐related behaviors and dynamic imbalance in mice. bioRxiv. 2023. doi:10.1101/2023.06.30.547257
Jones SM, Vijayakumar S, Dow SA, Holt JC, Jordan PM, Luebke AE. Loss of α‐calcitonin gene‐related peptide (αCGRP) reduces otolith activation timing dynamics and impairs balance. Front Mol Neurosci. 2018;11:289.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata‐driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377‐381.
Sharon JD, Krauter R, Kirk L, et al. Development and validation of VM‐PATHI: vestibular migraine patient assessment tool and handicap inventory. Otol Neurotol. 2020;41(4):e494‐e500.
Jacobson GP, Newman CW. The development of the dizziness handicap inventory. Arch Otolaryngol Head Neck Surg. 1990;116(4):424‐427.
Tamber AL, Wilhelmsen KT, Strand LI. Measurement properties of the dizziness handicap inventory by cross‐sectional and longitudinal designs. Health Qual Life Outcomes. 2009;7:101.
Rizk HG, Velozo C, Shah S, Hum M, Sharon JD, Mcrackan TR. Item level psychometrics of the dizziness handicap inventory in vestibular migraine and Meniere's disease. Ear Hear. 2024;45:106‐114. doi:10.1097/AUD.0000000000001405
Salviz M, Yuce T, Acar H, Karatas A, Acikalin RM. Propranolol and venlafaxine for vestibular migraine prophylaxis: a randomized controlled trial. Laryngoscope. 2016;126(1):169‐174.
Lepcha A, Amalanathan S, Augustine AM, Tyagi AK, Balraj A. Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. Eur Arch Otorrinolaringol. 2014;271(11):2931‐2936.
Yuan Q, Liu DL, Yu LS, Zhang QF. Flunarizine in the prophylaxis of vestibular migraine:a randomized controlled trial. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2016;30(10):805‐810.
Hoskin JL, Fife TD. New anti‐CGRP medications in the treatment of vestibular migraine. Front Neurol. 2021;12:799002.
Lovato A, Disco C, Frosolini A, Monzani D, Perini F. Monoclonal antibodies targeting CGRP: a novel treatment in vestibular migraine. Medicina. 2023;59(9):1560. doi:10.3390/medicina59091560
Warfvinge K, Edvinsson L. Distribution of CGRP and CGRP receptor components in the rat brain. Cephalalgia. 2019;39(3):342‐353.
Luebke AE, Holt JC, Jordan PM, Wong YS, Caldwell JS, Cullen KE. Loss of α‐calcitonin gene‐related peptide (αCGRP) reduces the efficacy of the Vestibulo‐ocular reflex (VOR). J Neurosci. 2014;34(31):10453‐10458.
Zhang Y, Zhang Y, Tian K, et al. Calcitonin gene‐related peptide facilitates sensitization of the vestibular nucleus in a rat model of chronic migraine. J Headache Pain. 2020;21(1):72.
He W, Long T, Pan Q, et al. Microglial NLRP3 inflammasome activation mediates IL‐1β release and contributes to central sensitization in a recurrent nitroglycerin‐induced migraine model. J Neuroinflammation. 2019;16(1):78.
Chiao W, Krauter R, Kirk L, Steenerson K, Pasquesi L, Sharon J. Understanding dizzy patients a cross‐sectional analysis of attitudes toward diagnosis, providers, and treatment. Ann Otol Rhinol Laryngol. 2022;131(4):352‐359.
Phillips J, Mikulec AA, Robinson JM, Skarinsky D, Anderson JJ. Efficacy of intratympanic OTO‐104 for the treatment of ménière's disease: the outcome of three randomized, double‐blind, placebo‐controlled studies. Otol Neurotol. 2023;44(6):584‐592.